Table 1.
Patient characteristics n (%)
| Neoadjuvant chemoradiotherapy (n = 12)1 | Non-neoadjuvant chemoradiotherapy (n = 45)1 | P value2 | |
| Demographic variables | |||
| Age (yr) | 59.0 (48.25, 62.75) | 67.0 (60.00, 69.00) | 0.02 |
| Age ≥ 60 | 6 (50.0) | 35 (77.8) | 0.08 |
| Sex (Male) | 8 (66.7) | 24 (53.3) | 0.41 |
| Follow-up duration (mo) | 31.9 (19.8, 53.8) | 26.4 (14.5, 42.1) | 0.27 |
| Laboratory variables | |||
| Albumin (g/dL) | 3.75 (3.450, 4.075) | 3.60 (3.200, 3.850) | 0.32 |
| Total bilirubin (mg/dL) | 2.3 (0.60, 8.45) | 6.4 (2.35, 11.40) | < 0.05 |
| CA 19-9 (U/mL) | 181.8 (27.08, 1452.50) | 210.0 (71.35, 976.00) | 0.74 |
| Cancer-related variables | |||
| Bismuth classification | |||
| IIIA | 2 (16.7) | 21 (46.7) | 0.10 |
| IIIB | 3 (25.0) | 2 (4.4) | 0.06 |
| IV | 7 (58.3) | 22 (48.9) | 0.56 |
| Pre-op AJCC 7th stage | |||
| IIIA (T3N0M0) | 8 (66.7) | 23 (51.1) | 0.34 |
| IIIB (T1-3N1M0) | 2 (16.7) | 17 (37.8) | 0.30 |
| IVA (T4N0-1M0) | 1 (8.3) | 3 (6.7) | > 0.99 |
| IVB (T1-4N2M0) | 1 (8.3) | 2 (4.4) | 0.52 |
| Tumor differentiation | < 0.01 | ||
| Well | 0 (0) | 11 (24.4) | |
| Moderately | 7 (58.3) | 29 (64.4) | |
| Poorly | 0 (0) | 5 (11.1) | |
| Undetermined | 5 (41.7) | 0 (0) | |
| Post-operative adjuvant treatment | 5 (41.7) | 27 (60.0) | 0.26 |
| Recurrence | 10 (83.3) | 31 (68.9) | 0.48 |
| OP site | 3 (30.0) | 11 (35.5) | |
| Liver | 2 (20.0) | 3 (9.7) | |
| Distant organ | 3 (30.0) | 9 (29.0) | |
| Carcinomatosis | 2 (20.0) | 8 (25.8) | |
1
Continuous variables were denoted median (Q1, Q3) and categorical variables were denoted number (%);
2
P values were determined using a Mann-Whitney test for continuous variables and a χ2 test (Fisher’s exact test, Pearson and Mantel-Haenszel χ2 test) for categorical variables. CA19-9: Carbohydrate antigen 19-9; AJCC: American Joint Committee on Cancer.